Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
The global peptide contract development and manufacturing organization (CDMO) market is estimated at 4.2 billion dollars in 2026, growing at fourteen percent annually, driven by surging GLP-1 demand and a deepening pipeline of peptide therapeutics. Capacity is the binding constraint: global SPPS manufacturing capacity is approximately 8.2 metric tons of peptide API per year, with Novo Nordisk and Eli Lilly consuming nearly forty percent of that capacity for in-house GLP-1 production. Understanding the CDMO landscape is essential for any peptide drug developer making build-vs-buy decisions.
The Big Three and Their Niches
CordenPharma | four hundred eighty million dollars | ~0.9 | Lipidated peptides, complex conjugates | Eli Lilly, Pfizer.
AmbioPharm | one hundred forty million dollars | ~0.3 | US-based GMP, peptide new chemical entities | Mid-size pharma.
The CDMO market is consolidating rapidly. Bachem’s acquisition of Albatros (2024) and PolyPeptide’s expansion into India (2025) reflect the industry-wide recognition that scale is the primary competitive advantage. A production line capable of manufacturing 100 kg/year of a 30-residue peptide API costs $80–150 million to build and 3–4 years to qualify. The barrier to entry is not peptide chemistry — it is capital.
Build vs. Buy Decision Framework
For peptide drug developers, the single most consequential manufacturing decision is whether to build in-house capacity or contract with a CDMO. The decision depends on four factors:
1. Peptide Complexity. Linear peptides under 20 residues can be reliably manufactured by any GMP-certified CDMO. Complex peptides — macrocycles, lipidated peptides, peptides containing non-canonical amino acids — require specialized expertise that only the top-tier CDMOs possess. Attempting to manufacture a macrocycle at a generic-focused CDMO is a common and costly mistake.
2. Volume Projections. At volumes below 10 kg/year, contracting is almost always more economical than building. At volumes above 100 kg/year — typical for a successful GLP-1 class drug — in-house manufacturing becomes competitive. The crossover point varies by peptide but typically falls between 50–100 kg/year.
3. IP Protection. In-house manufacturing provides stronger protection of proprietary synthesis methods. CDMOs are generally trustworthy with client IP, but they also work with competitors, creating unavoidable information leakage risks. Companies with genuinely novel chemistry should consider in-house manufacturing at lower volumes than the pure economics would suggest.
4. Timeline. Building a GMP peptide facility takes 3–5 years from site selection to FDA inspection. Contracting with an existing CDMO requires 6–12 months for tech transfer. For companies in Phase II with a 2028 BLA/NDA target, building is not an option — the facility would not be ready in time.
Expert Insight: The Capacity Trap
CDMO capacity data must be interpreted carefully. A CDMO may report “1.8 tons of annual capacity,” but this number aggregates reactors of vastly different scales: a dozen 50 mmol research reactors, several 500 mmol pilot reactors, and one or two 5,000 mmol production reactors. If the production reactors are already booked (as they increasingly are for GLP-1 manufacturing), that “1.8 tons” is effectively unavailable for a new client. The capacity that matters is not total nominal capacity — it is available production-scale capacity for your specific peptide class.
Experienced procurement teams ask one question first: “Can you show me open slots on your production-scale reactors for Q3 2027?” If the CDMO cannot answer this question with specific dates, assume their capacity is already allocated — regardless of what their marketing materials claim. The peptide CDMO market is effectively sold out for GLP-1 scale production through 2028.
[Natural sign-off — one sentence summary of why this matters.]
Further Reading
- Economics of Peptide API Manufacturing
- Flow Chemistry Meets SPPS — technology that could expand capacity
Last reviewed: June 2026. Peptide Proof Editorial Team.
